anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A manufacturing method of an aloe adventitious root is provided to induce an adventitious root from aloe and to increase the amount of aloe emodin and aloesin culturing in a culture medium. CONSTITUTION: Aloe plant explants are sterilized. The sterilized aloe plant explants are used to induce an adventitious root to dentate in a medium containing plant growth hormone and to be fertilized in a solid medium or a liquid medium. A precursor is treated where the aloe adventitious root is proliferated. The adventitious root in which a precursor is applied is treated with SA (salicylic acid). An adventitious root inducing culture medium is MS solid medium. The plant growth hormone is the combination of the BA (6-benzylaminopurine) and NAA (1-naphthalene acetic acid). The adventitious root is induced in the MS solid medium, in which 0.4 - 0.6mg/L of NAA and 0.1 - 0.3mg/L of BA are added, for 18-24 days. The solid medium is B5 solid medium. The aloe plant explants is an explants cut in half of a light-unexposed yellow part among the leafs of a young raw plant that is less than 20 cm. Proliferation in a liquid culture medium is suspension-cultured and executed in a MS liquid culture medium with 0.2 - 0.4mg/L IBA 0.2 - 0.4mg/L IBA added. The suspension culture is agitated at 40-60 rpm and cultured after washing the induced adventitious root with PVP(polyvinylpyrrolidone). The liquid culture medium is changed in an interval of 2 weeks.
To provide hair treatment methods suitable for modifying the inside of hair.SOLUTION: Provided is a hair treatment method that reduces a void of hair medulla by bringing a hair composition that contains components (A) and (B) and meets the requirements (i) and/or (ii) into contact with the hair. The component (A) is at least one selected from the group consisting of hydrolyzed proteins, amino acids, and derivatives thereof. The component (B) is a penetrant. (i) is to contain a reduced hydrolyzed protein that can act as a reducing agent, as component (A). (ii) is to further contain a reducing agent as component (C). The pH of the hair composition at 25°C is 3.0 or more and less than 8.0.SELECTED DRAWING: Figure 1
PCT No. PCT/GB90/01819 Sec. 371 Date Jul. 23, 1992 Sec. 102(e) Date Jul. 23, 1992 PCT Filed Nov. 23, 1990 PCT Pub. No. WO91/07969 PCT Pub. Date Jun. 13, 1991.Pharmaceutical compositions for topical use in the treatment of infections caused by Herpes virus comprising from 8 to 12% caffeine as active ingredient and a pharmaceutically acceptable topical excipient, the caffeine particles being less than 50  mu m in size or having a particle size distribution in which at least 90% of the particles have a mass median diameter of less than 9  mu m. Methods of treating patients suffering from Herpes infections in a tissue area, comprising topical application of the novel compositions, are also disclosed.
Participants will receive 0.09% cyclosporine drops dosed at bid for 16 weeks. Participants receive 3 IPL sessions at 3-weeks interval in the last 2 months of the study. IPL treatments will be given with Lumenis M22 with a 590nm filter, pulse duration of 6-50ms (3 pulses/trigger) and fluence will be determined set at 10 J/cm2. A plastic filter will recover the IPL prism, preventing the light to reach the skin of the participant.
Desminopathy R350P is a human myopathy that is characterized by the progressive loss of muscle fiber organization. This results in the loss of muscle size, mobility, and strength. In desminopathy, inflammation affects muscle homeostasis and repair, and contributes to progressive muscle deterioration. Mitochondria morphology was also suggested to affect desminopathy progression. Epicatechin (Epi)-a natural compound found in cacao-has been proposed to regulate inflammatory signaling and mitochondria morphology in human and animal models. Hence, we hypothesize chronic Epi consumption to improve inflammatory pathway and mitochondria morphology in the peripheral blood mononuclear cells (PBMCs) of a desminopathy R350P patient. We found that 12 weeks of Epi consumption partially restored TRL4 signaling, indicative of inflammatory signaling and mitochondria morphology in the desminopathy patient. Moreover, Epi consumption improved blood health parameters, including reduced HOMA-IR and IL-6 levels in the desminopathy patient. This indicates that Epi consumption could be a useful tool to slow disease progression in desminopathy patients.
This invention discloses a clinical pathway medical management system, comprising an expert group part, a medical care execution part and a hospital supervisory control part. The expert group part is in charge of establishing pathways, formulating template frameworks, determining clinic projects, determining deviation of the pathway and exiting the clinical pathway. The medical care execution part performs diagnosis, entering pathways, executing projects, processing deviation, and controlling exiting pathways. This clinical pathway medical management system is a best programmed and standardized medical check-up-and-treatment process which has a strict working order and an accurate schedule. With an aim for achieving an expected treatment effect and controlling cost, the clinical pathway medical management system is particularly applied for a specific illness or a surgery in the medical process on the basis of evidence-based medicine and. The clinical pathway medical management system also integrates with comprehensive quality management and constant quality improvement which are used as supervisory control means for preventing rehabilitation delay and resources waste, so that the patients can get the best medical care service. The clinical pathway medical management system turns a traditional flexible treatment into a standardized and normalized treatment plan.
Fatal encephalopathy has occurred in patients treated with high doses of thiotepa. Other central nervous system toxicities, such as headache, apathy, psychomotor retardation, disorientation, confusion, amnesia, hallucinations, drowsiness, somnolence, seizures, coma, inappropriate behaviour and forgetfulness have been reported to occur in a dose-dependent manner during or shortly after administration of high-dose thiotepa. Do not exceed the recommended dose of thiotepa. If severe or life-threatening central nervous system toxicity occurs, discontinue administration of thiotepa and provide supportive care.

Pediatric use information is approved for Adienne SA’s TEPADINA (thiotepa) for injection. However, due to Adienne SA’s marketing exclusivity rights, the drug product is not labeled with that information.
Carcinogenicity studies were conducted in mice and rats. In an 86-week female mouse study at sirolimus doses 30 to 120 times higher than the 2 mg daily clinical dose (adjusted for body surface area), there was a statistically significant increase in malignant lymphoma at all dose levels compared with controls. In a second mouse study at dosages that were approximately 3 to 16 times the clinical dose (adjusted for body surface area), hepatocellular adenoma and carcinoma in males were considered sirolimus-related. In the 104-week rat study at dosages equal to or lower than the clinical dose of 2 mg daily (adjusted for body surface area), there were no significant findings.

Sirolimus was not genotoxic in the  in vitro bacterial reverse mutation assay, the Chinese hamster ovary cell chromosomal aberration assay, the mouse lymphoma cell forward mutation assay, or the in vivo mouse micronucleus assay. 

Fertility was diminished slightly in both male and female rats following oral administration of sirolimus at doses approximately 10 times or 2 times, respectively, the clinical dose of 2 mg daily (adjusted for body surface area). In male rats, atrophy of testes, epididymides, prostate, seminiferous tubules and/or reduction in sperm counts were observed. In female rats, reduced size of ovaries and uteri was observed. Reduction of sperm count in male rats was reversible upon cessation of dosing in one study. Testicular tubular degeneration was also seen in a 4-week intravenous study of sirolimus in monkeys at doses that were approximately equal to the clinical dose (adjusted for body surface area).
The impact of COVID-19 on menstruation has received a high level of public and media interest. Despite this, uncertainty exists about the advice that women and people who menstruate should receive in relation to the expected impact of SARS-CoV-2 infection, long COVID or COVID-19 vaccination on menstruation. Furthermore, the mechanisms leading to these reported menstrual changes are poorly understood. This review evaluates the published literature on COVID-19 and its impact on menstrual bleeding, discussing the strengths and limitations of these studies. We present evidence consistent with SARS-CoV-2 infection and long COVID having an association with changes in menstrual bleeding parameters and that the impact of COVID vaccination on menstruation appears less significant. An overview of menstrual physiology and known causes of abnormal uterine bleeding (AUB) is provided before discussing potential mechanisms which may underpin the menstrual disturbance reported with COVID-19, highlighting areas for future scientific study. Finally, consideration is given to the effect that menstruation may have on COVID-19, including the impact of the ovarian sex hormones on acute COVID-19 severity and susceptibility and reported variation in long COVID symptoms across the menstrual cycle. Understanding the current evidence and addressing gaps in our knowledge in this area are essential to inform public health policy, direct the treatment of menstrual disturbance and facilitate development of new therapies, which may reduce the severity of COVID-19 and improve quality of life for those experiencing long COVID.
GLIADEL Wafer is an implant for intracranial use, containing carmustine, a nitrosourea alkylating agent, and polifeprosan, a biodegradable copolymer used to control the release of carmustine. It is a sterile, off-white to pale yellow wafer approximately 1.45 cm in diameter and 1 mm thick. Each wafer contains 7.7 mg of carmustine [1, 3-bis (2-chloroethyl)-1-nitrosourea, or BCNU] and 192.3 mg of a biodegradable polyanhydride copolymer. The copolymer, polifeprosan 20, consists of poly [bis (p-carboxyphenoxy)] propane and sebacic acid in a 20:80 molar ratio. Carmustine is homogeneously distributed in the copolymer matrix.

The structural formula for polifeprosan 20 is:

The structural formula for carmustine is:
Guillain-Barre syndrome (GBS) is an acute monophasic immune-mediated polyradiculoneuropathy characterized by rapidly evolving ascending weakness, mild sensory loss, and hypo- or areflexia, typically progressing to peak symptoms over the course of 4 weeks. The precise mechanism is unclear but is proposed to be an immune-mediated reaction with the generation of antibodies against peripheral nerves triggered by a preceding viral infection. Acute motor and sensory axonal neuropathy (AMSAN) is a rare and severe variant of Guillain-Barre syndrome with limited published literature. Discussion of risk factors for this subtype has not been done in a systematic way. This case report involves a 34-year-old, active duty, West African female, who immigrated to the United States in 2019. She presented with worsening diplopia, bilateral distal upper and lower extremity paresthesias as well as progressively worsening bilateral upper extremity weakness. Her clinical picture was complicated by constitutional symptoms, diffuse lymphadenopathy, no preceding viral illness, and marked clinical deterioration. Ultimately, she was diagnosed with acute motor and sensory axonal neuropathy in the setting of a new diagnosis of systemic lupus erythematosus, a rarely described association emphasizing the importance of a thorough evaluation for underlying causes of acute neurologic pathologies.
BACKGROUND: Total hip arthroplasty (THA) in teenagers is generally avoided. Nevertheless, recent THA procedures in a very young patient show improved functional outcomes and implant survival, resulting in lower revision rates. This review aims to present an overview of the available literature on THA in teenagers and to provide evidence to inform caregivers.
METHODS: In this systematic review, studies required a primary THA method and a teenage patient population. Studies must report at least one of the following outcome measures: functional outcomes, implant survival, and complications. In addition, demographic and surgical data were collected.
RESULTS: Sixteen studies were analyzed, including 2040 patients and 2379 hips, with an average 7.7-year follow-up. The mean patient age was 18 years, with an average revision rate of 11.7%. The overall average relative improvement of the 2 most frequently used patient-reported (functional) outcome measures were 84.3 and 92.3% at the latest follow-up. Prosthesis, or liner loosening, was the cause of revision in 50.2% of the cases. Loosening was the most frequent complication (14.8%), together with prosthesis/liner wear (14.8%). Cementless fixation (70.7%), ceramic-on-ceramic articulation (34.7%), and the posterior surgical approach (82.3%) were the most applied techniques.
CONCLUSIONS: The functional outcomes after THA in teenagers improved at follow-up. The average revision rate is relatively high, especially in the pre-1995 studies, with post-1995 studies reporting similar revision rates to the adult patient group. Research to further improve implant survival as well as the ease of revisions in teenagers is needed.
LEVEL OF EVIDENCE: Level III-systematic review.
The microbiome plays a crucial role in integrating environmental influences into host physiology, potentially linking it to autoimmune liver diseases, such as autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. All autoimmune liver diseases are associated with reduced diversity of the gut microbiome and altered abundance of certain bacteria. However, the relationship between the microbiome and liver diseases is bidirectional and varies over the course of the disease. This makes it challenging to dissect whether such changes in the microbiome are initiating or driving factors in autoimmune liver diseases, secondary consequences of disease and/or pharmacological intervention, or alterations that modify the clinical course that patients experience. Potential mechanisms include the presence of pathobionts, disease-modifying microbial metabolites, and more nonspecific reduced gut barrier function, and it is highly likely that the effect of these change during the progression of the disease. Recurrent disease after liver transplantation is a major clinical challenge and a common denominator in these conditions, which could also represent a window to disease mechanisms of the gut-liver axis. Herein, we propose future research priorities, which should involve clinical trials, extensive molecular phenotyping at high resolution, and experimental studies in model systems. Overall, autoimmune liver diseases are characterized by an altered microbiome, and interventions targeting these changes hold promise for improving clinical care based on the emerging field of microbiota medicine.
333,159. Soc. of Chemical Industry in Basle, Merki, W., and Scheidegger, P. April 2, 1929. Addition to 285,856. Medicines for internal use; manufacture of medicines.-The process described in the parent Specification for treating internal secretory organs of females by cooling by admixture with an indifferent refrigerating agent, such as solid carbonic acid, pulverizing them, if desired with addition of an agent which combines with water, and extracting the powder so obtained with a suitable solvent, is applied according to the present invention to the treatment of animal or vegetable materials generally, for the production of physiologically active extracts. Treatment of internal secretory sex organs of animals and the use of liquid gases as refrigerating agents are excluded. According to examples (1) anterior lobes of hypophysis glands are mixed with solid carbon dioxide, ground, and repeatedly extracted with strong alcohol; water is added to the extract and the alcohol expelled, and the emulsion so obtained is extracted with ether to yield lipoids and an aqueous fraction which is evaporated to dryness; (2) yeast is similarly treated to obtain a lipoid fraction which deposits crystals of ergosterol, and a delequescent watersoluble portion; (3) hearts of warm blooded animals are similarly frozen and powdered, and extracted with 60 per cent alcohol; protein is separated from the solution by addition of acetic acid, and lipoids are extracted with a water-insoluble solvent to leave an active aqueous extract; (4) bone marrow similarly frozen and ground is repeatedly extracted with strong ethyl or methyl alcohol, the alcohol is expelled from the extract by vacuum distillation, if desired with simultaneous addition of water, and the residual emulsion is extracted with ether or other solvent to obtain an oil; (5) ox spleen mixed with solid carbon dioxide and powdered is extracted with aqueous acetone, and the solution, freed from acetone, is extracted with ether to leave an aqueous solution which, after precipitation of proteins by addition of acetic acid, is evaporated to obtain a physiologically active powder, (6) fresh blood frozen and powdered is covered with strong alcohol, stirred during and after thawing and filtered to obtain an extract which is further treated, as in the first example, to yield a lipoid fraction and an aqueous fraction, the former of which accelerates coagulation of the blood.
Meets the NINCDS-ADRDA criteria for probable Alzheimer's disease; CDR-global score = 1; overall cognitive decline: MMSE score of 20-24; impaired daily living abilities: Activities of Daily Living (ADL) scale score \> 26. Signed informed consent form.
Forty patients with four or more brain metastases will be enrolled prior to radiosurgery. A planning MRI brain scan will be performed with GD-DPTA within one week prior to radiosurgery, per the standard of care. Neurocognitive (Mini-Mental Status Examination (MMSE), Trail-making test A\&B, Hopkins Learning Verbal (HVLT)) and functional assessment of cancer therapy-brain (FACT- Br) will be obtained prior to radiosurgery. Dose will be prescribed to the maximum isodose line encompassing the resulting PTV using the dose guidelines as described below.

The primary endpoint will be the proportion of patients who live longer than predicted based on the diagnosis-specific GPA score. The Kaplan-Meier estimator will be used to describe the survival of all patients treated with SIMT SRS. Secondary endpoints will be the rate of recurrence at the treated metastases sites, the rate of new brain metastases at a site different from the SRS-treated metastases sites, the rate of death due to neurological causes, and the prevalence of significant adverse events. Exploratory endpoints include change over time in neurocognition and quality of life, quantification of dosimetric measures, the rate of salvage therapy, the rate of radionecrosis at the SRS treatment sites, and the rate and intensity of steroid-usage post-SRS.

All patients will be evaluated for neurocognitive function via MMSE, HVLT, and Trail-making tests A \& B, quality of life via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study. These evaluations will be done at regular follow-up evaluations or when local recurrence is suspected on the basis of symptoms. Distant recurrence is defined as the appearance of new brain metastases at a site different from that of the original metastases. Recurrence will further be defined as a new area of enhancement that measures greater than 5 millimeters in the axial plane on MRI. The length of time to recurrence of the original brain metastases will be calculated from the date of the brain metastases radiosurgery to the date that a recurrence was detected by MRI. Patients with suspected recurrent tumor and/or who are symptomatic may undergo a stereotactic biopsy to evaluate for radionecrosis versus recurrent brain metastases, as is standard of care.
CREON is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, proteases, and amylases. 

Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble or insoluble in alcohol and ether. 

Each delayed-release capsule for oral administration contains enteric-coated spheres (0.71–1.60 mm in diameter). 

The active ingredient evaluated in clinical trials is lipase. CREON is dosed by lipase units. 

Other active ingredients include protease and amylase. 

CREON contains the following inactive ingredients: cetyl alcohol, dimethicone, hypromellose phthalate, polyethylene glycol, and triethyl citrate.

3,000 USP units of lipase; 9,500 USP units of protease; 15,000 USP units of amylase delayed-release capsules have a white opaque cap with imprint “CREON 1203” and a white opaque body. The shells contain titanium dioxide and hypromellose.

6,000 USP units of lipase; 19,000 USP units of protease; 30,000 USP units of amylase delayed-release capsules have a Swedish-orange opaque cap with imprint “CREON 1206” and a blue opaque body. The shells contain FD&C Blue No. 2, gelatin, red iron oxide, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide. 

12,000 USP units of lipase; 38,000 USP units of protease; 60,000 USP units of amylase delayed-release capsules have a brown opaque cap with imprint “CREON 1212” and a colorless transparent body. The shells contain black iron oxide, gelatin, red iron oxide, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide. 

24,000 USP units of lipase; 76,000 USP units of protease; 120,000 USP units of amylase delayed-release capsules have a Swedish-orange opaque cap with imprint “CREON 1224” and a colorless transparent body. The shells contain gelatin, red iron oxide, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide.
The safety experience in U.S. placebo-controlled trials included 1069 hypertensive patients, of whom 832 received MAVIK. Nearly 200 hypertensive patients received MAVIK for over one year in open-label trials. In controlled trials, withdrawals for adverse events were 2.1% on placebo and 1.4% on MAVIK. Adverse events considered at least possibly related to treatment occurring in 1% of MAVIK-treated patients and more common on MAVIK than placebo, pooled for all doses, are shown below, together with the frequency of discontinuation of treatment because of these events.

Headache and fatigue were all seen in more than 1% of MAVIK-treated patients but were more frequently seen on placebo. Adverse events were not usually persistent or difficult to manage.
The patient was a 73-year-old man who had undergone surgery for gastric cancer in January 2020 and was subsequently attending an outpatient clinic. In May, he presented with right upper abdominal pain. A computed tomography (CT) scan revealed an intraparenchymal rupture of a pseudoaneurysm in a segmental branch of the hepatic artery, and a transcatheter arterial embolization was performed. A follow-up CT scan in August showed a tumor in the same area. Retrospectively, the pseudoaneurysm in the segmental branch of the hepatic artery, which had experienced intraparenchymal rupture, was identified as the feeding artery for the tumor. In October, a right hepatic lobectomy was performed. Pathological examination confirmed a diagnosis of poorly differentiated hepatocellular carcinoma (HCC). This case highlights a rare instance of HCC causing intraparenchymal rupture.